Telmisartan inhibits hyperalgesia and inflammatory progression in a diabetic neuropathic pain model of Wistar rats

References

1. ↵
   1. Abdi S,
   2. Haruo A,
   3. Bloomstone J

   (2004) Electroconvulsive therapy for neuropathic pain: a case report and literature review. Pain Physician 7, 261–263.
2. ↵
   1. Woolf CJ

   (2004) Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 74, 2605–2610.
3. ↵
   1. Gilron I,
   2. Watson CP,
   3. Cahill CM,
   4. Moulin DE

   (2006) Neuropathic pain: a practical guide for the clinician. CMAJ 175, 265–275.
4. ↵
   1. Edwards JL,
   2. Vincent AM,
   3. Cheng HT,
   4. Feldman EL

   (2008) Diabetic neuropathy: mechanisms to management. Pharmacol Ther 120, 1–34.
5. ↵
   1. Zoungas S,
   2. Patel A

   (2010) Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci 1212, 29–40.
6. ↵
   1. Maxfield EK,
   2. Love A,
   3. Cotter MA,
   4. Cameron NE

   (1995) Nerve function and regeneration in diabetic rats: effects of ZD-7155, an AT1 receptor antagonist. Am J Physiol 269, E530–E537.
7. ↵
   1. Reinecke K,
   2. Lucius R,
   3. Reinecke A,
   4. Rickert U,
   5. Herdegen T,
   6. Unger T

   (2003) Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 17, 2094–2096.
8. ↵
   1. Murphy GJ,
   2. Holder JC

   (2000) PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21, 469–474.
9. ↵
   1. Yamagishi S,
   2. Ogasawara S,
   3. Mizukami H,
   4. Yajima N,
   5. Wada R,
   6. Sugawara A,
   7. et al.

   (2008) Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J Neurochem 104, 491–499.
10. ↵
    1. Imayama I,
    2. Ichiki T,
    3. Inanaga K,
    4. Ohtsubo H,
    5. Fukuyama K,
    6. Ono H,
    7. et al.

    (2006) Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 72, 184–190.
11. ↵
    1. Mulay SR,
    2. Gaikwad AB,
    3. Tikoo K

    (2010) Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Chemico-Biological Interactions 185, 137–142.
12. ↵
    1. Kurihara T,
    2. Ozawa Y,
    3. Shinoda K,
    4. Nagai N,
    5. Inoue M,
    6. Oike Y,
    7. et al.

    (2006) Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci 47, 5545–5552.
13. ↵
    1. Ola MS,
    2. Ahmed MM,
    3. Abuohashish HM,
    4. Al-Rejaie SS,
    5. Alhomida AS

    (2013) Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats. Neurochem Res 38, 1572–1579.
14. ↵
    1. Mahmood D,
    2. Akhtar M,
    3. Vohora D,
    4. Khanam R

    (2010) Comparison of antinociceptive and antidiabetic effects of sertraline and amitriptyline on streptozotocin-induced diabetic rats. Hum Exp Toxicol 29, 881–886.
15. ↵
    1. Sugimoto K,
    2. Rashid IB,
    3. Shoji M,
    4. Suda T,
    5. Yasujima M

    (2008) Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats. J Pain 9, 237–245.
16. ↵
    1. Kamboj SS,
    2. Vasishta RK,
    3. Sandhir R

    (2010) N-acetylcysteine inhibits hyperglycemia-induced oxidative stress and apoptosis markers in diabetic neuropathy. J Neurochem 112, 77–91.
17. ↵
    1. Kapoor R,
    2. Srivastava S,
    3. Kakkar P

    (2009) Bacopa monnieri modulates antioxidant responses in brain and kidney of diabetic rats. Environ Toxicol Pharmacol 27, 62–69.
18. ↵
    1. Lenzen S

    (2008) The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51, 216–226.
19. ↵
    1. Cameron NE,
    2. Tuck Z,
    3. McCabe L,
    4. Cotter MA

    (2001) Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 44, 1161–1169.
20. ↵
    1. Calcutt NA,
    2. Freshwater JD,
    3. Mizisin AP

    (2004) Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47, 718–724.
21. ↵
    1. Cameron NE,
    2. Jack AM,
    3. Cotter MA

    (2001) Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 31, 125–135.
22. ↵
    1. Li F,
    2. Drel VR,
    3. Szabo C,
    4. Stevens MJ,
    5. Obrosova IG

    (2005) Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 54, 1514–1522.
23. ↵
    1. Obrosova IG

    (2009) Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 6, 638–647.
24. ↵
    1. Chaplan SR,
    2. Bach FW,
    3. Pogrel JW,
    4. Chung JM,
    5. Yaksh TL

    (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53, 55–63.
25. ↵
    1. Pacifici L,
    2. Bellucci A,
    3. Piovesan P,
    4. Maccari F,
    5. Gorio A,
    6. Ramacci MT

    (1992) Counteraction on experimentally induced diabetic neuropathy by levocarnitine acetyl. Int J Clin Pharmacol Res 12, 231–236.
26. ↵
    1. Ohsawa M,
    2. Kamei J

    (1999) Possible involvement of spinal protein kinase C in thermal allodynia and hyperalgesia in diabetic mice. Eur J Pharmacol 372, 221–228.
27. ↵
    1. Freeman RS,
    2. Burch RL,
    3. Crowder RJ,
    4. Lomb DJ,
    5. Schoell MC,
    6. Straub JA,
    7. et al.

    (2004) NGF deprivation-induced gene expression: after ten years, where do we stand? Prog Brain Res 146, 111–126.
28. ↵
    1. Benson SC,
    2. Pershadsingh HA,
    3. Ho CI,
    4. Chittiboyina A,
    5. Desai P,
    6. Pravenec M,
    7. et al.

    (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43, 993–1002.
29. ↵
    1. Rotman N,
    2. Wahli W

    (2010) PPAR modulation of kinase-linked receptor signaling in physiology and disease. Physiology (Bethesda) 25, 176–185.
30. ↵
    1. Ricote M,
    2. Li AC,
    3. Willson TM,
    4. Kelly CJ,
    5. Glass CK

    (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79–82.
31. ↵
    1. Wang P,
    2. Anderson PO,
    3. Chen S,
    4. Paulsson KM,
    5. Sjögren HO,
    6. Li S

    (2001) Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol 1, 803–812.
32. ↵
    1. Paterniti I,
    2. Impellizzeri D,
    3. Crupi R,
    4. Morabito R,
    5. Campolo M,
    6. Esposito E,
    7. et al.

    (2013) Molecular evidence for the involvement of PPAR-d and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J Neuroinflammation 10, 20.
33. ↵
    1. Al Rouq F,
    2. El Eter E

    (2014) PPAR-γ activator induces neuroprotection in hypercholesterolemic rats subjected to global cerebral ischemia/reperfusion injury: in vivo and in vitro inhibition of oxidative stress. Exp Gerontol 51, 1–7.
34. ↵
    1. Li J,
    2. Wei GH,
    3. Huang H,
    4. Lan YP,
    5. Liu B,
    6. Liu H,
    7. et al.

    (2013) Nerve injury-related autoimmunity activation leads to chronic inflammation and chronic neuropathic pain. Anesthesiology 118, 416–429.
35. ↵
    1. Locksley RM,
    2. Killeen N,
    3. Lenardo MJ

    (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501.
36. ↵
    1. Navarro-Gonzalez JF,
    2. Mora-Fernandez C

    (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19, 433–442.
37. ↵
    1. Pang T,
    2. Benicky J,
    3. Wang J,
    4. Orecna M,
    5. Sanchez-Lemus E,
    6. Saavedra JM

    (2012) Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes. J Hypertens 30, 87–96.
38. ↵
    1. Araújo AA,
    2. Souza TO,
    3. Moura LM,
    4. Brito GA,
    5. Aragão KS,
    6. Araújo LS,
    7. et al.

    (2013) Effect of telmisartan on levels of IL-1, TNF-a, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model. J Clin Periodontol 40, 1104–1111.